Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc

Antiviral Research

Volumn 112, Issue , 2014, Pages 80-90

  Latinovic, Olga ^a   Schneider, Kate ^a   Szmacinski, Henryk ^a   Lakowicz, Joseph R ^a   Heredia, Alonso ^a   Redfield, Robert R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

CCR5; CCR5 antagonist; Fusion protein; HIV 1; Maraviroc

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5; DYE; FULL LENGTH SINGLE CHAIN IMMUNOGLOBULIN G1 FUSIUON PROTEIN; HYBRID PROTEIN; MARAVIROC; UNCLASSIFIED DRUG; CCR5 PROTEIN, HUMAN; CD4 ANTIGEN; CYCLOHEXANE DERIVATIVE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G; PROTEIN BINDING; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRIAZOLE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL ADHESION; CELL DENSITY; CONFOCAL MICROSCOPY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG CONFORMATION; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; EC50; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MICROSCOPY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA HALF LIFE; PRIMARY CELL; STOCHASTIC OPTICAL RECONSTRUCTION MICROSCOPY; SURFACE PROPERTY; VIRION; VIRUS ATTACHMENT; VIRUS CORE; VIRUS ENTRY; CELL LINE; DRUG EFFECTS; GENETICS; METABOLISM; PHYSIOLOGY; PROCEDURES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIGENS, CD4; CELL LINE; CYCLOHEXANES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNOGLOBULIN G; MICROSCOPY, CONFOCAL; PROTEIN BINDING; RECEPTORS, CCR5; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; TRIAZOLES; VIRUS INTERNALIZATION;

EID: 84909987082     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.10.006     Document Type: Article

References (45)

1. A. Ashkenazi, and S.M. Chamow Immunoadhesins as research tools and therapeutic agents Curr. Opin. Immunol. 9 1997 195 200
2. B.P. Burke, M.P. Boyd, H. Impet, L.R. Breton, J.S. Bartlett, G.P. Saymonds, and G. Hutter CCR5 as a natural and modulated target for inhibition of HIV Viruses 30 2013 54 68
3. M. Cavrois, M.C. De Noronha, and W.C. Greene A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes Nat. Biotechnol. 20 2002 1151 1154
4. T. Dragic, V. Litwin, G.P. Allaway, S.R. Martin, Y. Huang, K.A. Nagashima, C. Cayanan, J.P. Maddon, R.A. Koup, J.P. Moore, and W.A. Paxton HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 Nature 381 1996 667 673
5. D.M. Eckert, and P.S. Kim Mechanisms of viral membrane fusion and its inhibition Annu. Rev. Biochem. 70 2001 777 810
6. M.J. Endres, P.J. Clapham, M. Marsh, M. Ahuja, J.D. Turner, A. McKnight, J.F. Thomas, B. Stoegenau-Haggarty, S. Choe, P.J. Vance, T.N.C. Wells, C.A. Power, S.S. Sutterwala, R.W. Doms, N.R. Landau, and J.A. Hoxie CD4-independent infection by HIV-2 is mediated by Fusin/CXCR4 Cell 87 1996 745 756
7. T.R. Fouts, R. Tuskan, K. Godfrey, M. Reitz, D. Hone, G. Lewis, and A.L. DeVico Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex J. Virol. 74 2000 11427 11436
8. W. Gong, O.M. Howard, J.A. Turpin, M.C. Grimm, H. Ueda, P.W. Gray, C.J. Raport, J.J. Oppenhein, and J.M. Wang Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication J. Biol. Chem. 273 1998 4289 4292
9. P.R. Gorry, A. Ellett, and S.R. Lewin Maraviroc L. Grayson, S. Crowe, J. McCarthy, J. Mills, J. Mouton, S.R. Norrby, D. Paterson, M. Pfaller, Kucers' The Use of Antibiotics 2010 Hodder & Stoughton Ltd. London 2869 2876
10. A. Heredia, A. Amoroso, C. Davis, N. Le, E. Reardon, E. Dominique, R.C. Gallo, and R.R. Redfield Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1 Proc. Natl. Acad. Sci. U.S.A. 100 2003 10411 10416
11. F. Hladik, H. Liu, E. Speelmon, D. Livingston-Rosanoff, S. Wilson, P. Sacchalathron, Y. Hwangbo, B. Greene, T. Zhu, and M.J. McElrath Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism-2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission J. Virol. 79 2005 11677 11684
12. C.C. Huang, S.N. Lam, P. Acharya, M. Tang, S.H. Xiang, S.S. Hussan, R.L. Stanfield, J. Robinson, J. Sodroski, I.A. Wilson, R. Wyatt, C.A. Bewley, and P.D. Kwong Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4 Science 317 2007 1930 1934
13. C. Ji, J. Zhang, M. Dioszegi, S. Chiu, E. Rao, E. Rao, A. Derosier, N. Cammack, M. Bradtt, and S. Sankurati CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor Mol. Pharmacol. 72 2007 18 28
14. J. Kimpton, and M. Emerman Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene J. Virol. 66 1992 2232 2239
15. S.E. Kuhmann, E.J. Platt, S.L. Kozak, and D. Kabet Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1 J. Virol. 74 2000 7005 7015
16. H.W. Lahm, and S. Stein Characterization of recombinant human interleukin-2 with micromethods J. Chromatogr. 326 1985 357 361
17. O. Latinovic, N. Le, M. Reitz, R. Pal, A.L. DeVico, J.S. Foulke, R.R. Redfield, and A. Heredia Synergistic inhibition of R5 HIV-1 by Maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention AIDS 25 2011 1232 1235
18. O. Latinovic, M. Reitz, N.M. Le, J.S. Foulke, G. Fatkenheuer, C. Lehman, R.R. Redfield, and A. Heredia CCR5 antibodies HGS004 and HGS001 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells Virology 411 2011 32 40
19. Latinovic, O., Zhang, J., Tagaya, Y., DeVico, A.L., Fouts, T.R., Schneider, K., Lakowicz, J.R., Heredia, A., Redfield, R.R., Synergistic inhibition of R5 HIV-1 by the fusion protein FLSC IgG1 Fc and Maraviroc in primary cells: Implications for prevention and treatment, submitted for publication.
20. B. Lee, M. Sharron, L.J. Montaner, D. Weissman, and R.W. Doms Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages Proc. Natl. Acad. Sci. U.S.A. 96 1999 5215 5220
21. B. Lee, M. Sharron, C. Blanpain, B.J. Doranz, J. Vakili, P. Setoh, E. Berg, G. Liu, H.R. Guy, S.R. Durell, M. Parmentier, C.N. Chang, K. Price, M. Tsang, and R.W. Doms Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function J. Biol. Chem. 274 1999 9617 9626
22. R. Liu, W.A. Paxton, S. Choe, D. Ceradini, S.R. Martin, R. Horuk, M.E. McDonald, H. Stuhlmann, R.A. Koup, and N.R. Landau Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection Cell 86 1996 367 377
23. M.H. Malim, J. Hauber, R. Fenrick, and B.R. Cullen Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes Nature 335 1988 181 183
24. N.L. Michael, L.G. Louie, and H.W. Sheppard CCR5-delta 32 gene deletion in HIV-1 infected patients Lancet 350 1997 741 742
25. J.P. Moore, and R.W. Doms The entry of entry inhibitors: a fusion of science and medicine Proc. Natl. Acad. Sci. U.S.A. 100 2003 10598 10602
26. C.F. Pereira, J. Rossy, D.M. Owen, J. Mark, and K. Gaus HIV taken by STORM: super-resolution fluorescence microscopy of a viral infection Virol. J. 9 2012 84 92
27. E.J. Platt, K. Wehrly, S.E. Kuhmann, B. Chesebro, and D. Kabat Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1 J. Virol. 72 1998 2855 2864
28. E.J. Platt, D.M. Shea, P.P. Rose, and D. Kabat Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan J. Virol. 79 2005 4357 4568
29. E.J. Platt, M.M. Gomes, and D. Kabat Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms J. Virol. 88 2014 4304 4318
30. P. Pugach, T.J. Ketas, E. Michael, and J.P. Moore Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors Virology 377 2008 401 407
31. J. Reynes, V. Baillat, P. Portales, J. Clot, and P. Corbeau Relationship between CCR5 density and viral load after discontinuation of antiretroviral therapy JAMA 291 2004 46 50
32. N.H. Roy, J. Chan, M. Lambele, and M. Thali Clustering and mobility of HIV-1 Env at viral assembly sites predict its propensity to induce cell-cell fusion J. Virol. 87 2013 7516 7525
33. M.J. Rust, M. Bates, and X. Zhuang Stochastic optical reconstruction microscopy (STORM) provides sub-diffraction-limit image resolution Nat. Methods 3 2006 793 795
34. G.M. Shaw, and E. Hunter HIV transmission Cold Spring Harb. Perspect. Med. 2 2012 a006965
35. S.J. Siciliano, S.E. Kuhmann, Y. Weng, N. Madani, M.S. Springer, J.E. Lineberger, R. Danzeisen, M.D. Miler, M.P. Kavanaugh, J.A. DeMArtino, and D. Kabat A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type I J. Biol. Chem. 274 1999 1905 1913
36. H. Szmacinski, R. Badugu, F. Mahdavi, S. Blair, and J.R. Lakowicz Large fluorescence enhancements of fluorophore ensembles with multilayer plasmonic substrates: comparison of theory and experimental results J. Phys. Chem. C 116 2012 21563 21571
37. H. Szmacinski, V. Toshchakov, W. Piao, and J.R. Lakowicz Imaging of protein secretion from a single cell using plasmonic substrates Bionanoscience 3 2013 30 36
38. Q. Tan, Y. Zhu, J. Li, Z. Chen, G.W. Han, I. Kufareva, L. Tingting, M. Limin, G. Fenalti, J. Li, W. Zhang, X. Xie, H. Yang, H. Jiang, V. Cherezov, H. Liu, R.C. Stevens, Q. Zhao, and B. Wu Structure of the CCR5 chemokine receptor-HIV entry inhibitor Maraviroc complex Science 341 2013 1387 1390
39. B.M. Taylor, J.S. Foulke, R. Flinko, A. Heredia, A.L. DeVico, and M. Reitz An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence J. Virol. 82 2008 5460 5471
40. M. Tobiume, J.E. Lineberger, C.A. Lundquist, M.D. Miller, and C. Aiken Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cells J. Virol. 77 2003 10645 10650
41. J.R. Vu, T. Fouts, K. Bobb, J. Burns, and A.L. DeVico An immunoglobulin fusion protein based on the gp120-CD4 receptor complex potently inhibits human immunodeficiency virus type 1 in vitro AIDS Res. Hum. Retroviruses 22 2006 477 490
42. M. Westby, C. Smith-Burchnell, J. Mori, M. Lewis, and M. Mosley Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist Maraviroc utilize inhibitor-bound receptor for entry J. Virol. 81 2006 2359 2371
43. A. Wood, and D. Armour The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS Prog. Med. Chem. 43 2005 239 271
44. L. Wu, W.A. Paxton, N. Kassam, N. Ruffing, J.B. Rottman, N. Sullivan, H. Choe, J. Sodroski, W. Newman, R.A. Koup, and C.R. Mackay CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro J. Exp. Med. 185 1997 1681 1692
45. Y.R. Zou, A.H. Kottmann, M. Kuroda, I. Taniuchi, and D.R. Littman Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development Nature 393 1998 595 599